RICHMOND, Va. / Mar 01, 2023 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) announced today that executive leadership will participate in a fireside chat at the upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference. The discussion will take place on Thursday, March 2 at 8:45 a.m. Eastern Time.
Please visit the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-presentations/ at least ten minutes in advance to register for the live webcast of the discussion. A replay of the webcast can be accessed following the presentation at the link provided above.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company integrating product manufacturing and delivery, home health supply and perioperative services to support care through the hospital and into the home. Owens & Minor drives visibility, control and efficiency for patients, providers and healthcare professionals across the supply chain with proprietary technology and solutions, an extensive product portfolio, an Americas-based manufacturing footprint for personal protective equipment (PPE) and surgical products, as well as a robust portfolio of products and services for patients managing chronic and acute conditions in the home setting. Operating continuously since 1882 from its headquarters in Richmond, Va., Owens & Minor is a 140-year-old company powered by more than 20,000 global teammates. Learn more at https://www.owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.
| Last Trade: | US$3.15 |
| Daily Change: | 0.04 1.29 |
| Daily Volume: | 2,024,178 |
| Market Cap: | US$243.650M |
October 30, 2025 October 07, 2025 September 15, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load